End-stage kidney disease undergoing hemodialysis or peritoneal dialysis with renal anemia.
Conditions
Interventions
1,000 mg dose of levocarnitine by injection three times a week after hemodialysis
Control (no levocarnitine therapy)
Sponsors
Nihon University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) who received hemodialysis or peritoneal dialysis in our hospitals, (2) whose medical decisions were made at our hospitals, and (3) who were 20 to 85 years of age.
Exclusion criteria
Exclusion criteria: (1) patients who had previously taken levocarnitine, either orally or injected; (2) patients who were taking carnitine or zinc preparation as a supplement; (3) patients who have difficulty communicating owing to dementia or other factors; (4) patients with acute inflammation; (5) patients taking an immunosuppressive drug, steroid, or antibiotic; and (6) patients with a history of blood transfusion within the past six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of carnitine deficincy, Physical function, lean body mass, BMI | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythropoietin responsiveness index, Dose of erythropiesis stimulating agents, Hemoglobin, and zinc level | — |
Countries
Japan
Contacts
Public ContactTerumi Higuchi
Keiai Hospital Nephrology
Outcome results
None listed